摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-(4-Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic acid

中文名称
——
中文别名
——
英文名称
1-[2-(4-Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic acid
英文别名
1-[2-(4-fluorophenyl)ethyl]pyrazole-4-carboxylic acid
1-[2-(4-Fluoro-phenyl)-ethyl]-1H-pyrazole-4-carboxylic acid化学式
CAS
——
化学式
C12H11FN2O2
mdl
——
分子量
234.23
InChiKey
NVTCBHPCRAPQOZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity
    申请人:Vernalis (R&D) Ltd.
    公开号:US20150099736A1
    公开(公告)日:2015-04-09
    Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R 1 , R 2 , R 5 and R 6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino; R 3 , and R 4 are independently selected from hydrogen, hydroxy, C 1 -C 3 alkyl, fluoro-(C 1 -C 3 )-alkyl, hydroxy-(C 1 -C 3 )-alkyl, C 1 -C 3 alkoxy, fluoro-(C 1 -C 3 )-alkoxy, hydroxy-(C 1 -C 3 )-alkoxy, —N(R 11 )—R 12 , -Alk-N(R 11 )—R 12 , —O-Alk-N(R 11 )—R 12 , —C(═O)OH, carboxy-(C 1 -C 3 )-alkyl, or —C(═O)—NH—R 13 ; Alk is a straight or branched chain divalent C 1 -C 6 alkylene radical; R 7 and R 8 are independently selected from hydrogen, hydroxy, or C 1 -C 3 alkoxy; X is a straight chain divalent C 1 -C 3 alkylene radical, optionally substituted on one or more carbons by R 9 and/or R 10 ; W is selected from —C(═O)—N(—R 16 )— or —N(—R 17 )—C(═O)—; Y is hydrogen, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, or halo; and Q is selected from optionally substituted phenyl, optionally substituted cyclohexyl, or an optionally substituted 6-membered monocyclic heteroaryl ring.
    公式(I)的化合物具有检查点激酶1(CHK1)抑制活性:其中R1、R2、R5和R6分别选自氢、羟基、甲基、三甲基、羟甲基、甲氧基、三甲氧基、甲基基和二甲氨基;R3和R4分别选自氢、羟基、C1-C3烷基、代(C1-C3)烷基、羟基(C1-C3)烷基、C1-C3烷氧基、代(C1-C3)烷氧基、羟基(C1-C3)烷氧基、-N(R11)-R12,-Alk-N(R11)-R12,-O-Alk-N(R11)-R12,-C(=O)OH,羧基(C1-C3)烷基或-C(=O)-NH-R13;Alk是直链或支链的二价C1-C6烷基基团;R7和R8分别选自氢、羟基或C1-C3烷氧基;X是直链的二价C1-C3烷基基团,可在一个或多个碳上取代R9和/或R10;W选自-C(=O)-N(-R16)-或-N(-R17)-C(=O)-;Y选自氢、C1-C3烷基、C1-C3烷氧基或卤素;Q选自可选取代的苯基、可选取代的环己基或可选取代的6元单环杂芳基。
  • Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
    申请人:Vernalis (R&D) Ltd.
    公开号:US10696652B2
    公开(公告)日:2020-06-30
    A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:
    一种治疗患有对蛋白激酶活性抑制有反应的癌症的哺乳动物的方法,向该哺乳动物施用一定量的式(I)化合物或其药学上可接受的盐,以有效抑制蛋白激酶活性,其中式(I)化合物是:
  • INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY
    申请人:Vernalis (R&D) Ltd.
    公开号:EP2294065B1
    公开(公告)日:2014-03-19
  • US8916591B2
    申请人:——
    公开号:US8916591B2
    公开(公告)日:2014-12-23
  • US9604975B2
    申请人:——
    公开号:US9604975B2
    公开(公告)日:2017-03-28
查看更多